Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
Drug-Eluting Stents | 82 | 2024 | 681 | 8.640 |
Why?
|
Angioplasty, Balloon, Coronary | 89 | 2024 | 1725 | 7.540 |
Why?
|
Stents | 110 | 2024 | 3179 | 6.620 |
Why?
|
Coronary Restenosis | 54 | 2024 | 396 | 4.660 |
Why?
|
Coronary Thrombosis | 34 | 2024 | 440 | 3.980 |
Why?
|
Sirolimus | 53 | 2022 | 1533 | 3.970 |
Why?
|
Coronary Artery Disease | 69 | 2024 | 6403 | 3.300 |
Why?
|
Coronary Stenosis | 28 | 2020 | 794 | 2.930 |
Why?
|
Myocardial Infarction | 98 | 2022 | 11461 | 2.780 |
Why?
|
Cardiovascular Agents | 24 | 2024 | 840 | 2.270 |
Why?
|
Platelet Aggregation Inhibitors | 47 | 2024 | 2751 | 2.220 |
Why?
|
Paclitaxel | 28 | 2016 | 1732 | 2.070 |
Why?
|
Endpoint Determination | 22 | 2019 | 590 | 1.910 |
Why?
|
Creatine Kinase, MB Form | 14 | 2019 | 202 | 1.610 |
Why?
|
Renal Artery Obstruction | 10 | 2019 | 219 | 1.490 |
Why?
|
Prosthesis Design | 41 | 2024 | 2115 | 1.480 |
Why?
|
Coated Materials, Biocompatible | 7 | 2024 | 311 | 1.370 |
Why?
|
Myocardial Revascularization | 11 | 2020 | 790 | 1.320 |
Why?
|
Coronary Angiography | 64 | 2023 | 4471 | 1.310 |
Why?
|
Hemorrhage | 30 | 2024 | 3424 | 1.290 |
Why?
|
Acute Coronary Syndrome | 10 | 2023 | 2190 | 1.190 |
Why?
|
Clinical Trials as Topic | 34 | 2022 | 8002 | 1.140 |
Why?
|
Platelet Glycoprotein GPIIb-IIIa Complex | 17 | 2015 | 577 | 1.090 |
Why?
|
Heart Valve Prosthesis Implantation | 16 | 2023 | 1553 | 1.080 |
Why?
|
Aspirin | 21 | 2021 | 3133 | 1.030 |
Why?
|
Polymers | 7 | 2022 | 1616 | 1.020 |
Why?
|
Treatment Outcome | 157 | 2024 | 64685 | 1.000 |
Why?
|
Intermittent Claudication | 7 | 2015 | 304 | 0.940 |
Why?
|
Thrombosis | 22 | 2022 | 2942 | 0.910 |
Why?
|
Coronary Disease | 29 | 2019 | 5914 | 0.890 |
Why?
|
Immunosuppressive Agents | 22 | 2018 | 4176 | 0.890 |
Why?
|
Endarterectomy, Carotid | 10 | 2018 | 555 | 0.880 |
Why?
|
Troponin | 5 | 2012 | 502 | 0.770 |
Why?
|
Absorbable Implants | 8 | 2022 | 338 | 0.770 |
Why?
|
Product Surveillance, Postmarketing | 2 | 2017 | 452 | 0.750 |
Why?
|
Equipment and Supplies | 3 | 2018 | 273 | 0.710 |
Why?
|
Time Factors | 77 | 2024 | 39969 | 0.700 |
Why?
|
Metals | 6 | 2019 | 719 | 0.700 |
Why?
|
Risk Assessment | 52 | 2024 | 23996 | 0.680 |
Why?
|
Coronary Vessels | 9 | 2021 | 3096 | 0.680 |
Why?
|
Terminology as Topic | 9 | 2019 | 1530 | 0.670 |
Why?
|
Carotid Stenosis | 8 | 2018 | 860 | 0.660 |
Why?
|
Iliac Artery | 3 | 2015 | 343 | 0.640 |
Why?
|
Humans | 288 | 2024 | 761596 | 0.600 |
Why?
|
Follow-Up Studies | 69 | 2024 | 39106 | 0.570 |
Why?
|
Device Approval | 2 | 2016 | 163 | 0.560 |
Why?
|
Middle Aged | 161 | 2024 | 220921 | 0.540 |
Why?
|
Cardiology | 4 | 2018 | 1656 | 0.540 |
Why?
|
Aged | 137 | 2024 | 169310 | 0.540 |
Why?
|
Pyridines | 11 | 2019 | 2875 | 0.540 |
Why?
|
Angioplasty | 9 | 2015 | 355 | 0.540 |
Why?
|
Ticlopidine | 9 | 2017 | 730 | 0.530 |
Why?
|
Risk Factors | 76 | 2024 | 74213 | 0.530 |
Why?
|
Kaplan-Meier Estimate | 28 | 2017 | 6484 | 0.530 |
Why?
|
Blood Vessel Prosthesis Implantation | 12 | 2018 | 1428 | 0.520 |
Why?
|
Graft Occlusion, Vascular | 9 | 2011 | 537 | 0.500 |
Why?
|
Constriction, Pathologic | 6 | 2015 | 1096 | 0.490 |
Why?
|
Diabetes Complications | 5 | 2012 | 1315 | 0.490 |
Why?
|
Death | 5 | 2022 | 676 | 0.480 |
Why?
|
Financial Management | 1 | 2016 | 160 | 0.480 |
Why?
|
Male | 173 | 2024 | 360846 | 0.480 |
Why?
|
Prospective Studies | 58 | 2024 | 54423 | 0.470 |
Why?
|
Embolism | 9 | 2013 | 399 | 0.470 |
Why?
|
Postoperative Complications | 22 | 2018 | 15633 | 0.470 |
Why?
|
Fibromuscular Dysplasia | 1 | 2014 | 55 | 0.460 |
Why?
|
Heart Atria | 7 | 2024 | 1345 | 0.460 |
Why?
|
Female | 174 | 2024 | 392705 | 0.460 |
Why?
|
Stroke | 18 | 2024 | 9758 | 0.450 |
Why?
|
Stroke Volume | 10 | 2024 | 5496 | 0.430 |
Why?
|
Registries | 19 | 2020 | 8225 | 0.430 |
Why?
|
Renal Insufficiency, Chronic | 7 | 2023 | 2242 | 0.430 |
Why?
|
Drug Therapy, Combination | 20 | 2024 | 6312 | 0.430 |
Why?
|
Accreditation | 1 | 2016 | 473 | 0.420 |
Why?
|
Aortic Valve | 9 | 2024 | 1955 | 0.420 |
Why?
|
Diabetic Angiopathies | 3 | 2013 | 803 | 0.420 |
Why?
|
Cerebral Revascularization | 2 | 2012 | 259 | 0.420 |
Why?
|
Donor Selection | 1 | 2014 | 232 | 0.410 |
Why?
|
Patient Selection | 13 | 2017 | 4244 | 0.400 |
Why?
|
Academies and Institutes | 2 | 2012 | 318 | 0.400 |
Why?
|
Myocardial Ischemia | 8 | 2015 | 2113 | 0.400 |
Why?
|
Unnecessary Procedures | 1 | 2015 | 415 | 0.400 |
Why?
|
Angina Pectoris, Variant | 1 | 2011 | 53 | 0.400 |
Why?
|
Proportional Hazards Models | 23 | 2017 | 12463 | 0.400 |
Why?
|
Consensus | 10 | 2024 | 3124 | 0.400 |
Why?
|
Coronary Circulation | 8 | 2015 | 1569 | 0.380 |
Why?
|
Diabetes Mellitus | 8 | 2019 | 5841 | 0.370 |
Why?
|
Heart Failure | 11 | 2024 | 11671 | 0.370 |
Why?
|
United States Food and Drug Administration | 4 | 2018 | 1664 | 0.360 |
Why?
|
Randomized Controlled Trials as Topic | 26 | 2020 | 10212 | 0.360 |
Why?
|
Creatine Kinase | 6 | 2013 | 685 | 0.350 |
Why?
|
Cardiovascular Diseases | 13 | 2018 | 15502 | 0.350 |
Why?
|
Single-Blind Method | 18 | 2018 | 1574 | 0.350 |
Why?
|
Biomedical Research | 3 | 2017 | 3429 | 0.350 |
Why?
|
Fractional Flow Reserve, Myocardial | 2 | 2012 | 323 | 0.350 |
Why?
|
Drug Delivery Systems | 9 | 2013 | 2226 | 0.350 |
Why?
|
Hemodynamics | 1 | 2020 | 4160 | 0.350 |
Why?
|
Aorta | 2 | 2015 | 2041 | 0.350 |
Why?
|
Heart-Assist Devices | 2 | 2023 | 1287 | 0.340 |
Why?
|
Hypothermia, Induced | 2 | 2011 | 753 | 0.330 |
Why?
|
Decision Support Techniques | 3 | 2016 | 1998 | 0.330 |
Why?
|
Peripheral Arterial Disease | 7 | 2017 | 1273 | 0.330 |
Why?
|
Peer Review, Research | 1 | 2012 | 340 | 0.320 |
Why?
|
Coronary Artery Bypass | 11 | 2020 | 2188 | 0.320 |
Why?
|
Kidney Failure, Chronic | 5 | 2016 | 2472 | 0.320 |
Why?
|
Hydroxymethylglutaryl-CoA Reductase Inhibitors | 3 | 2023 | 3246 | 0.320 |
Why?
|
Aortic Valve Stenosis | 9 | 2024 | 2001 | 0.300 |
Why?
|
Atherosclerosis | 7 | 2023 | 3407 | 0.300 |
Why?
|
Survival Rate | 16 | 2019 | 12723 | 0.290 |
Why?
|
Heart Valve Prosthesis | 6 | 2018 | 1462 | 0.290 |
Why?
|
Troponin T | 4 | 2019 | 780 | 0.280 |
Why?
|
Flavins | 2 | 2023 | 18 | 0.280 |
Why?
|
Angioplasty, Balloon | 7 | 2013 | 589 | 0.280 |
Why?
|
Research Design | 13 | 2023 | 6180 | 0.270 |
Why?
|
Predictive Value of Tests | 18 | 2019 | 15266 | 0.270 |
Why?
|
Europe | 13 | 2023 | 3420 | 0.270 |
Why?
|
Incidence | 22 | 2017 | 21355 | 0.270 |
Why?
|
Prostheses and Implants | 1 | 2013 | 1271 | 0.260 |
Why?
|
Tissue and Organ Procurement | 1 | 2014 | 962 | 0.260 |
Why?
|
Ventricular Fibrillation | 1 | 2008 | 537 | 0.260 |
Why?
|
United States | 45 | 2023 | 72340 | 0.260 |
Why?
|
Heart Arrest | 2 | 2016 | 1514 | 0.250 |
Why?
|
Drug Administration Schedule | 7 | 2024 | 4853 | 0.250 |
Why?
|
Atherectomy, Coronary | 6 | 2003 | 137 | 0.250 |
Why?
|
Severity of Illness Index | 20 | 2020 | 15843 | 0.250 |
Why?
|
Nanoparticles | 1 | 2017 | 1958 | 0.240 |
Why?
|
Electrocardiography | 14 | 2018 | 6377 | 0.240 |
Why?
|
Glomerular Filtration Rate | 6 | 2023 | 2178 | 0.240 |
Why?
|
Luciferases | 2 | 2023 | 714 | 0.240 |
Why?
|
Logistic Models | 16 | 2015 | 13255 | 0.230 |
Why?
|
Medication Adherence | 2 | 2019 | 2176 | 0.230 |
Why?
|
Double-Blind Method | 21 | 2018 | 12341 | 0.230 |
Why?
|
Education, Medical, Graduate | 1 | 2016 | 2373 | 0.230 |
Why?
|
Tubulin Modulators | 3 | 2013 | 107 | 0.220 |
Why?
|
Heart Diseases | 1 | 2016 | 2781 | 0.210 |
Why?
|
Accidents, Traffic | 1 | 2008 | 816 | 0.210 |
Why?
|
Multivariate Analysis | 14 | 2019 | 12059 | 0.210 |
Why?
|
Practice Guidelines as Topic | 6 | 2016 | 7391 | 0.200 |
Why?
|
Blood Vessel Prosthesis | 4 | 2018 | 951 | 0.200 |
Why?
|
Clinical Competence | 3 | 2016 | 4793 | 0.200 |
Why?
|
New Zealand | 6 | 2015 | 358 | 0.190 |
Why?
|
Exercise Therapy | 3 | 2015 | 929 | 0.190 |
Why?
|
Saphenous Vein | 5 | 2008 | 516 | 0.190 |
Why?
|
Equipment Design | 14 | 2024 | 3511 | 0.190 |
Why?
|
Vasodilator Agents | 2 | 2016 | 973 | 0.190 |
Why?
|
Diagnostic Imaging | 2 | 2015 | 3530 | 0.190 |
Why?
|
Myocardial Reperfusion | 3 | 2010 | 338 | 0.190 |
Why?
|
Angiotensin II Type 1 Receptor Blockers | 2 | 2014 | 431 | 0.190 |
Why?
|
Out-of-Hospital Cardiac Arrest | 2 | 2017 | 339 | 0.180 |
Why?
|
Calgranulin A | 1 | 2021 | 80 | 0.180 |
Why?
|
Tyrosine | 2 | 2012 | 1440 | 0.180 |
Why?
|
Calgranulin B | 1 | 2021 | 86 | 0.180 |
Why?
|
Venous Thromboembolism | 1 | 2014 | 1866 | 0.180 |
Why?
|
Isoenzymes | 2 | 2004 | 1687 | 0.180 |
Why?
|
Renal Artery | 3 | 2023 | 351 | 0.180 |
Why?
|
Hypertension | 8 | 2023 | 8540 | 0.170 |
Why?
|
Inpatients | 2 | 2010 | 2548 | 0.170 |
Why?
|
Odds Ratio | 9 | 2015 | 9647 | 0.170 |
Why?
|
Exercise Test | 3 | 2013 | 2127 | 0.170 |
Why?
|
Survival Analysis | 13 | 2018 | 10090 | 0.170 |
Why?
|
Asia | 4 | 2023 | 619 | 0.160 |
Why?
|
Postoperative Care | 2 | 2017 | 1468 | 0.160 |
Why?
|
Sex Factors | 9 | 2018 | 10554 | 0.160 |
Why?
|
Thienopyridines | 1 | 2018 | 9 | 0.160 |
Why?
|
Data Collection | 4 | 2018 | 3322 | 0.160 |
Why?
|
P-Selectin | 1 | 2021 | 597 | 0.150 |
Why?
|
Cause of Death | 5 | 2019 | 3683 | 0.150 |
Why?
|
Prosthesis Implantation | 2 | 2023 | 592 | 0.150 |
Why?
|
Retreatment | 5 | 2013 | 598 | 0.150 |
Why?
|
Coronary Occlusion | 1 | 2021 | 304 | 0.150 |
Why?
|
Australia | 6 | 2013 | 1250 | 0.150 |
Why?
|
Prosthesis Failure | 7 | 2014 | 1204 | 0.140 |
Why?
|
Endovascular Procedures | 4 | 2019 | 2183 | 0.140 |
Why?
|
Cardiovascular Surgical Procedures | 1 | 2018 | 189 | 0.140 |
Why?
|
Alloys | 2 | 2014 | 110 | 0.140 |
Why?
|
Anticoagulants | 4 | 2024 | 4812 | 0.140 |
Why?
|
Vascular Diseases | 3 | 2022 | 1161 | 0.140 |
Why?
|
Fibrinolytic Agents | 3 | 2021 | 2084 | 0.130 |
Why?
|
Atrial Fibrillation | 3 | 2024 | 5127 | 0.130 |
Why?
|
Equipment Safety | 4 | 2011 | 249 | 0.130 |
Why?
|
Internship and Residency | 1 | 2016 | 5882 | 0.130 |
Why?
|
Cost-Benefit Analysis | 10 | 2016 | 5493 | 0.130 |
Why?
|
Organophosphorus Compounds | 1 | 2017 | 206 | 0.130 |
Why?
|
Albuminuria | 2 | 2016 | 658 | 0.130 |
Why?
|
Chi-Square Distribution | 4 | 2013 | 3415 | 0.130 |
Why?
|
Mitral Valve Insufficiency | 2 | 2015 | 1400 | 0.130 |
Why?
|
Antineoplastic Agents, Phytogenic | 4 | 2016 | 621 | 0.130 |
Why?
|
Bayes Theorem | 4 | 2017 | 2330 | 0.130 |
Why?
|
Brain Ischemia | 2 | 2021 | 3049 | 0.130 |
Why?
|
Confidence Intervals | 5 | 2016 | 2927 | 0.130 |
Why?
|
Myocardium | 2 | 2012 | 4725 | 0.130 |
Why?
|
Angiotensin-Converting Enzyme Inhibitors | 4 | 2016 | 1516 | 0.120 |
Why?
|
Multicenter Studies as Topic | 6 | 2013 | 1702 | 0.120 |
Why?
|
Thrombectomy | 3 | 2008 | 705 | 0.120 |
Why?
|
Hypertension, Renal | 1 | 2015 | 135 | 0.120 |
Why?
|
Internationality | 2 | 2017 | 1001 | 0.120 |
Why?
|
Retrospective Studies | 15 | 2020 | 80647 | 0.120 |
Why?
|
Popliteal Artery | 2 | 2014 | 310 | 0.120 |
Why?
|
Treatment Failure | 5 | 2013 | 2643 | 0.120 |
Why?
|
Preoperative Care | 1 | 2003 | 2242 | 0.120 |
Why?
|
Medical Audit | 1 | 2015 | 453 | 0.120 |
Why?
|
Congresses as Topic | 1 | 2019 | 803 | 0.110 |
Why?
|
Aged, 80 and over | 19 | 2019 | 58984 | 0.110 |
Why?
|
Recurrence | 11 | 2019 | 8466 | 0.110 |
Why?
|
Quality of Life | 14 | 2023 | 13367 | 0.110 |
Why?
|
Bioprosthesis | 1 | 2018 | 591 | 0.110 |
Why?
|
Nitrates | 1 | 2015 | 263 | 0.110 |
Why?
|
Sensitivity and Specificity | 7 | 2013 | 14665 | 0.110 |
Why?
|
Carotid Arteries | 2 | 2015 | 941 | 0.110 |
Why?
|
Shock | 1 | 2016 | 314 | 0.110 |
Why?
|
Ultrasonography, Doppler, Duplex | 1 | 2014 | 198 | 0.110 |
Why?
|
Femoral Artery | 3 | 2014 | 826 | 0.110 |
Why?
|
Smoking | 6 | 2017 | 9053 | 0.110 |
Why?
|
Chromium Alloys | 2 | 2016 | 71 | 0.110 |
Why?
|
Thiophenes | 2 | 2014 | 569 | 0.110 |
Why?
|
Asymptomatic Diseases | 1 | 2016 | 588 | 0.100 |
Why?
|
Massachusetts | 7 | 2016 | 8833 | 0.100 |
Why?
|
Combined Modality Therapy | 7 | 2019 | 8527 | 0.100 |
Why?
|
Vasoconstrictor Agents | 1 | 2016 | 654 | 0.100 |
Why?
|
Reproducibility of Results | 9 | 2021 | 20100 | 0.100 |
Why?
|
Coronary Vessel Anomalies | 1 | 2015 | 307 | 0.100 |
Why?
|
Consensus Development Conferences as Topic | 1 | 2012 | 168 | 0.100 |
Why?
|
Reference Standards | 2 | 2012 | 1003 | 0.100 |
Why?
|
Diagnostic Self Evaluation | 1 | 2013 | 224 | 0.100 |
Why?
|
Comorbidity | 9 | 2018 | 10508 | 0.090 |
Why?
|
Safety | 3 | 2019 | 1149 | 0.090 |
Why?
|
Kidney | 4 | 2023 | 7048 | 0.090 |
Why?
|
Cardiology Service, Hospital | 1 | 2013 | 239 | 0.090 |
Why?
|
Israel | 3 | 2008 | 726 | 0.090 |
Why?
|
Peptides | 2 | 2012 | 4358 | 0.090 |
Why?
|
Vascular Patency | 3 | 2024 | 911 | 0.090 |
Why?
|
Prognosis | 9 | 2023 | 29629 | 0.090 |
Why?
|
Nervous System Diseases | 2 | 2018 | 1667 | 0.090 |
Why?
|
Reimbursement Mechanisms | 1 | 2016 | 667 | 0.090 |
Why?
|
Autopsy | 2 | 2011 | 1009 | 0.090 |
Why?
|
Coronary Care Units | 1 | 2011 | 235 | 0.090 |
Why?
|
Interinstitutional Relations | 1 | 2011 | 236 | 0.090 |
Why?
|
Health Care Costs | 3 | 2014 | 3242 | 0.090 |
Why?
|
Filtration | 2 | 2008 | 228 | 0.080 |
Why?
|
Feasibility Studies | 4 | 2015 | 5247 | 0.080 |
Why?
|
Credentialing | 1 | 2010 | 116 | 0.080 |
Why?
|
Renin-Angiotensin System | 1 | 2014 | 737 | 0.080 |
Why?
|
Health Services | 1 | 2014 | 752 | 0.080 |
Why?
|
Sex Distribution | 1 | 2014 | 2280 | 0.080 |
Why?
|
Disease-Free Survival | 7 | 2012 | 6815 | 0.080 |
Why?
|
Organizational Objectives | 1 | 2011 | 426 | 0.080 |
Why?
|
Echocardiography | 5 | 2024 | 4989 | 0.080 |
Why?
|
Angiography | 1 | 2014 | 1595 | 0.080 |
Why?
|
Myocardial Perfusion Imaging | 4 | 2016 | 575 | 0.080 |
Why?
|
Regional Blood Flow | 1 | 2012 | 1496 | 0.080 |
Why?
|
Aortic Diseases | 1 | 2014 | 735 | 0.080 |
Why?
|
False Positive Reactions | 1 | 2011 | 957 | 0.080 |
Why?
|
Regression Analysis | 5 | 2012 | 6345 | 0.080 |
Why?
|
Age Distribution | 1 | 2014 | 2879 | 0.080 |
Why?
|
Age Factors | 8 | 2016 | 18399 | 0.080 |
Why?
|
Societies, Medical | 5 | 2018 | 3905 | 0.080 |
Why?
|
Antihypertensive Agents | 2 | 2015 | 2024 | 0.080 |
Why?
|
Urokinase-Type Plasminogen Activator | 2 | 2001 | 325 | 0.080 |
Why?
|
Platelet Activation | 1 | 2011 | 645 | 0.080 |
Why?
|
Ultrasonography, Interventional | 6 | 2014 | 1496 | 0.080 |
Why?
|
Disease Management | 3 | 2015 | 2508 | 0.070 |
Why?
|
Hydrocortisone | 1 | 2016 | 1819 | 0.070 |
Why?
|
Cooperative Behavior | 2 | 2014 | 1505 | 0.070 |
Why?
|
Hospitals, Teaching | 1 | 2012 | 1156 | 0.070 |
Why?
|
Boston | 3 | 2017 | 9327 | 0.070 |
Why?
|
Imaging, Three-Dimensional | 1 | 2020 | 4062 | 0.070 |
Why?
|
Atherectomy | 2 | 2015 | 42 | 0.070 |
Why?
|
Education | 1 | 2010 | 537 | 0.070 |
Why?
|
Lower Extremity | 1 | 2015 | 1202 | 0.070 |
Why?
|
Shock, Cardiogenic | 2 | 2023 | 709 | 0.070 |
Why?
|
Mitral Valve | 1 | 2015 | 1465 | 0.070 |
Why?
|
Phosphorylcholine | 1 | 2007 | 153 | 0.070 |
Why?
|
Piperazines | 2 | 2014 | 2523 | 0.070 |
Why?
|
Catheterization, Peripheral | 1 | 2010 | 343 | 0.070 |
Why?
|
Cardiovascular Abnormalities | 1 | 2007 | 143 | 0.070 |
Why?
|
Acute Disease | 5 | 2008 | 7237 | 0.070 |
Why?
|
District of Columbia | 2 | 2019 | 159 | 0.070 |
Why?
|
Diagnostic Tests, Routine | 1 | 2012 | 787 | 0.070 |
Why?
|
Carotid Artery Diseases | 1 | 2012 | 877 | 0.070 |
Why?
|
Obesity | 2 | 2023 | 12947 | 0.070 |
Why?
|
Hospitalization | 7 | 2018 | 10721 | 0.060 |
Why?
|
Advisory Committees | 2 | 2014 | 787 | 0.060 |
Why?
|
Models, Cardiovascular | 1 | 2011 | 981 | 0.060 |
Why?
|
World Health Organization | 1 | 2012 | 1322 | 0.060 |
Why?
|
Radiology, Interventional | 1 | 2010 | 476 | 0.060 |
Why?
|
Guideline Adherence | 1 | 2016 | 2220 | 0.060 |
Why?
|
Walking | 4 | 2015 | 1198 | 0.060 |
Why?
|
Reperfusion Injury | 1 | 2012 | 1023 | 0.060 |
Why?
|
Peripheral Vascular Diseases | 1 | 2008 | 488 | 0.060 |
Why?
|
Drug Implants | 1 | 2005 | 230 | 0.060 |
Why?
|
Adult | 18 | 2022 | 221210 | 0.060 |
Why?
|
Quality Improvement | 2 | 2020 | 3802 | 0.060 |
Why?
|
Kidney Function Tests | 1 | 2007 | 679 | 0.060 |
Why?
|
Intention to Treat Analysis | 2 | 2017 | 413 | 0.060 |
Why?
|
Renal Insufficiency | 1 | 2010 | 809 | 0.060 |
Why?
|
Tissue Donors | 1 | 2014 | 2332 | 0.060 |
Why?
|
Disease Progression | 3 | 2019 | 13510 | 0.060 |
Why?
|
Emergency Treatment | 2 | 2008 | 496 | 0.060 |
Why?
|
Prevalence | 4 | 2014 | 15733 | 0.060 |
Why?
|
Spectroscopy, Near-Infrared | 1 | 2009 | 740 | 0.060 |
Why?
|
Statistics as Topic | 2 | 2013 | 2358 | 0.050 |
Why?
|
Erythrocytes | 1 | 2013 | 2413 | 0.050 |
Why?
|
Endosonography | 1 | 2007 | 609 | 0.050 |
Why?
|
Cardiopulmonary Resuscitation | 3 | 2017 | 993 | 0.050 |
Why?
|
Time | 2 | 2002 | 546 | 0.050 |
Why?
|
Sampling Studies | 1 | 2004 | 615 | 0.050 |
Why?
|
Kidney Diseases | 2 | 2011 | 2091 | 0.050 |
Why?
|
Vascular Surgical Procedures | 2 | 2010 | 1489 | 0.050 |
Why?
|
Cohort Studies | 12 | 2015 | 41495 | 0.050 |
Why?
|
Ventricular Remodeling | 2 | 2023 | 1267 | 0.050 |
Why?
|
Dinucleoside Phosphates | 1 | 2022 | 72 | 0.050 |
Why?
|
Anemia, Pernicious | 1 | 1981 | 15 | 0.050 |
Why?
|
Immunoglobulin Fab Fragments | 2 | 2015 | 445 | 0.050 |
Why?
|
Hospital Mortality | 4 | 2012 | 5293 | 0.050 |
Why?
|
Heart Valve Diseases | 1 | 2009 | 1027 | 0.050 |
Why?
|
Ischemia | 2 | 2022 | 1884 | 0.040 |
Why?
|
Ventricular Function, Left | 2 | 2023 | 3879 | 0.040 |
Why?
|
American Heart Association | 2 | 2015 | 1039 | 0.040 |
Why?
|
Linear Models | 4 | 2016 | 5872 | 0.040 |
Why?
|
Mass Screening | 1 | 2016 | 5429 | 0.040 |
Why?
|
Statistics, Nonparametric | 2 | 2010 | 2850 | 0.040 |
Why?
|
Heart | 2 | 2023 | 4404 | 0.040 |
Why?
|
Hemostasis, Surgical | 1 | 2000 | 126 | 0.040 |
Why?
|
Paris | 1 | 2019 | 41 | 0.040 |
Why?
|
Hyperlipidemias | 1 | 2004 | 771 | 0.040 |
Why?
|
Quality-Adjusted Life Years | 3 | 2014 | 1722 | 0.040 |
Why?
|
Blood Pressure | 4 | 2016 | 8481 | 0.040 |
Why?
|
Brachytherapy | 1 | 2007 | 1223 | 0.040 |
Why?
|
Pulmonary Circulation | 1 | 2022 | 737 | 0.040 |
Why?
|
Platelet Function Tests | 1 | 2021 | 271 | 0.040 |
Why?
|
CD40 Ligand | 1 | 2021 | 522 | 0.040 |
Why?
|
New York | 1 | 2001 | 874 | 0.040 |
Why?
|
Kidney Transplantation | 1 | 2014 | 4235 | 0.040 |
Why?
|
Hypotension, Orthostatic | 1 | 1981 | 258 | 0.040 |
Why?
|
Anti-Inflammatory Agents | 1 | 2008 | 1809 | 0.040 |
Why?
|
Models, Economic | 2 | 2014 | 716 | 0.040 |
Why?
|
Lipids | 1 | 2009 | 3341 | 0.040 |
Why?
|
Thromboembolism | 1 | 2024 | 995 | 0.040 |
Why?
|
Contrast Media | 1 | 2011 | 5307 | 0.040 |
Why?
|
Postoperative Hemorrhage | 1 | 2021 | 415 | 0.040 |
Why?
|
Medicare | 1 | 2016 | 6770 | 0.040 |
Why?
|
Recovery of Function | 3 | 2015 | 2979 | 0.040 |
Why?
|
Blood Platelets | 1 | 2008 | 2479 | 0.040 |
Why?
|
Catheters, Indwelling | 1 | 2000 | 426 | 0.040 |
Why?
|
Exercise | 2 | 2015 | 5890 | 0.040 |
Why?
|
Hypertension, Portal | 1 | 2019 | 226 | 0.040 |
Why?
|
Reoperation | 2 | 2004 | 4303 | 0.030 |
Why?
|
Netherlands | 2 | 2012 | 2221 | 0.030 |
Why?
|
Adenosine | 1 | 2021 | 808 | 0.030 |
Why?
|
Administration, Oral | 1 | 2024 | 4021 | 0.030 |
Why?
|
Plasminogen Activators | 1 | 1996 | 199 | 0.030 |
Why?
|
Sutures | 1 | 2018 | 284 | 0.030 |
Why?
|
Health Services Accessibility | 2 | 2011 | 5440 | 0.030 |
Why?
|
Angina Pectoris | 2 | 2011 | 959 | 0.030 |
Why?
|
Anti-Inflammatory Agents, Non-Steroidal | 1 | 2006 | 2273 | 0.030 |
Why?
|
Canada | 2 | 2015 | 2122 | 0.030 |
Why?
|
Radiography | 3 | 2015 | 6965 | 0.030 |
Why?
|
South Africa | 2 | 2015 | 1843 | 0.030 |
Why?
|
Echocardiography, Stress | 1 | 2016 | 134 | 0.030 |
Why?
|
Control Groups | 1 | 2015 | 104 | 0.030 |
Why?
|
Withholding Treatment | 1 | 2019 | 617 | 0.030 |
Why?
|
Suture Techniques | 1 | 2000 | 769 | 0.030 |
Why?
|
Health Insurance Portability and Accountability Act | 1 | 2015 | 105 | 0.030 |
Why?
|
Egypt | 1 | 2015 | 97 | 0.030 |
Why?
|
Western Australia | 1 | 2014 | 41 | 0.030 |
Why?
|
South America | 1 | 2015 | 179 | 0.030 |
Why?
|
Neurologic Examination | 1 | 2018 | 916 | 0.030 |
Why?
|
ROC Curve | 1 | 2002 | 3578 | 0.030 |
Why?
|
Drug Monitoring | 1 | 2021 | 962 | 0.030 |
Why?
|
Causality | 1 | 2001 | 1242 | 0.030 |
Why?
|
Hypoglycemic Agents | 1 | 2007 | 3085 | 0.030 |
Why?
|
Risk | 3 | 2015 | 9610 | 0.030 |
Why?
|
Endarterectomy | 1 | 2015 | 196 | 0.030 |
Why?
|
Medicine | 2 | 2015 | 942 | 0.030 |
Why?
|
Health Status Indicators | 2 | 2015 | 970 | 0.030 |
Why?
|
Echocardiography, Doppler, Color | 1 | 2015 | 352 | 0.030 |
Why?
|
Aortic Valve Insufficiency | 1 | 2018 | 576 | 0.030 |
Why?
|
Amlodipine | 1 | 2013 | 84 | 0.030 |
Why?
|
Workflow | 1 | 2018 | 851 | 0.030 |
Why?
|
Mortality | 2 | 2017 | 2902 | 0.030 |
Why?
|
Italy | 1 | 2015 | 842 | 0.030 |
Why?
|
Insulin | 1 | 2007 | 6597 | 0.030 |
Why?
|
Neointima | 1 | 2013 | 133 | 0.030 |
Why?
|
Catheterization | 1 | 2018 | 1428 | 0.030 |
Why?
|
Quality Assurance, Health Care | 2 | 2015 | 2169 | 0.030 |
Why?
|
Erythrocyte Count | 1 | 2013 | 157 | 0.030 |
Why?
|
Neovascularization, Pathologic | 1 | 2002 | 2645 | 0.030 |
Why?
|
History, 20th Century | 1 | 2000 | 2767 | 0.030 |
Why?
|
Fibrosis | 1 | 2019 | 2049 | 0.020 |
Why?
|
Heptanoic Acids | 1 | 2013 | 344 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2003 | 3575 | 0.020 |
Why?
|
Tissue Scaffolds | 1 | 2018 | 934 | 0.020 |
Why?
|
Thrombocytopenia | 1 | 2019 | 1182 | 0.020 |
Why?
|
Confidentiality | 1 | 2015 | 609 | 0.020 |
Why?
|
Catheter Ablation | 1 | 2004 | 2751 | 0.020 |
Why?
|
Arterial Occlusive Diseases | 1 | 2015 | 748 | 0.020 |
Why?
|
San Francisco | 1 | 2011 | 162 | 0.020 |
Why?
|
Heart Injuries | 1 | 2012 | 206 | 0.020 |
Why?
|
Up-Regulation | 1 | 2019 | 4125 | 0.020 |
Why?
|
Software Validation | 1 | 2010 | 59 | 0.020 |
Why?
|
Young Adult | 2 | 2014 | 59260 | 0.020 |
Why?
|
Warfarin | 1 | 1998 | 1483 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 2 | 2013 | 10766 | 0.020 |
Why?
|
Anemia | 1 | 2019 | 1509 | 0.020 |
Why?
|
Secondary Prevention | 1 | 2016 | 1475 | 0.020 |
Why?
|
Cholesterol, HDL | 1 | 2016 | 1814 | 0.020 |
Why?
|
Angiotensin Receptor Antagonists | 1 | 2016 | 1039 | 0.020 |
Why?
|
Expert Testimony | 1 | 2012 | 364 | 0.020 |
Why?
|
Acute Kidney Injury | 2 | 2012 | 1924 | 0.020 |
Why?
|
Analysis of Variance | 2 | 2008 | 6228 | 0.020 |
Why?
|
Purinergic P2Y Receptor Antagonists | 1 | 2011 | 284 | 0.020 |
Why?
|
Hospitals, Community | 1 | 2011 | 365 | 0.020 |
Why?
|
Databases, Factual | 2 | 2015 | 7968 | 0.020 |
Why?
|
Anti-Bacterial Agents | 1 | 2007 | 7406 | 0.020 |
Why?
|
Quality of Health Care | 2 | 2015 | 4331 | 0.020 |
Why?
|
Postoperative Period | 1 | 2013 | 1814 | 0.020 |
Why?
|
Hospital Costs | 1 | 2014 | 947 | 0.020 |
Why?
|
Ultrasonography | 2 | 2012 | 5971 | 0.020 |
Why?
|
Health Status | 2 | 2017 | 4077 | 0.020 |
Why?
|
Propensity Score | 1 | 2015 | 1913 | 0.020 |
Why?
|
Life Expectancy | 1 | 2014 | 1243 | 0.020 |
Why?
|
Drug Combinations | 1 | 2013 | 2048 | 0.020 |
Why?
|
Emergency Service, Hospital | 2 | 2011 | 7879 | 0.020 |
Why?
|
Pyrroles | 1 | 2013 | 1125 | 0.020 |
Why?
|
Thrombolytic Therapy | 1 | 1996 | 2064 | 0.020 |
Why?
|
Ischemic Attack, Transient | 1 | 2012 | 882 | 0.020 |
Why?
|
Comprehension | 1 | 2012 | 621 | 0.020 |
Why?
|
Academic Medical Centers | 1 | 2017 | 2759 | 0.020 |
Why?
|
Iatrogenic Disease | 1 | 2010 | 540 | 0.020 |
Why?
|
Hemoglobins | 1 | 2013 | 1526 | 0.020 |
Why?
|
Antibodies, Monoclonal | 2 | 2015 | 9177 | 0.020 |
Why?
|
Health Status Disparities | 1 | 2018 | 1853 | 0.020 |
Why?
|
Pilot Projects | 3 | 2012 | 8633 | 0.020 |
Why?
|
Anticholesteremic Agents | 1 | 2013 | 966 | 0.020 |
Why?
|
Drug Costs | 1 | 2014 | 1183 | 0.020 |
Why?
|
Hyperplasia | 1 | 2009 | 1152 | 0.020 |
Why?
|
Blood Transfusion | 1 | 2013 | 1301 | 0.020 |
Why?
|
Creatinine | 1 | 2011 | 1899 | 0.020 |
Why?
|
Activities of Daily Living | 2 | 2008 | 2421 | 0.020 |
Why?
|
Case-Control Studies | 2 | 2017 | 22176 | 0.020 |
Why?
|
Platelet Count | 1 | 2008 | 781 | 0.020 |
Why?
|
Tunica Intima | 1 | 2007 | 459 | 0.020 |
Why?
|
Algorithms | 2 | 2009 | 14033 | 0.010 |
Why?
|
Smoking Cessation | 1 | 2016 | 2057 | 0.010 |
Why?
|
Eligibility Determination | 1 | 2008 | 421 | 0.010 |
Why?
|
Information Dissemination | 1 | 2012 | 1126 | 0.010 |
Why?
|
Health Planning Guidelines | 1 | 2004 | 151 | 0.010 |
Why?
|
Ambulatory Care | 1 | 2014 | 2775 | 0.010 |
Why?
|
Angina, Unstable | 1 | 2007 | 888 | 0.010 |
Why?
|
Belgium | 1 | 2002 | 118 | 0.010 |
Why?
|
Quebec | 1 | 2002 | 141 | 0.010 |
Why?
|
Arrhythmias, Cardiac | 1 | 2012 | 2244 | 0.010 |
Why?
|
Medical Staff, Hospital | 1 | 2006 | 601 | 0.010 |
Why?
|
Adrenergic beta-Antagonists | 1 | 2008 | 1241 | 0.010 |
Why?
|
Drug Utilization | 1 | 2008 | 1188 | 0.010 |
Why?
|
Infusions, Intra-Arterial | 1 | 2001 | 221 | 0.010 |
Why?
|
Patient Care Team | 1 | 2012 | 2521 | 0.010 |
Why?
|
Hemorheology | 1 | 2001 | 144 | 0.010 |
Why?
|
Tomography, Optical Coherence | 1 | 2014 | 2917 | 0.010 |
Why?
|
Emergency Medical Services | 1 | 2012 | 1923 | 0.010 |
Why?
|
Heart Rate | 1 | 2012 | 4195 | 0.010 |
Why?
|
Neural Conduction | 1 | 1981 | 441 | 0.010 |
Why?
|
Cineangiography | 1 | 1999 | 108 | 0.010 |
Why?
|
Cost of Illness | 1 | 2009 | 1937 | 0.010 |
Why?
|
Probability | 1 | 2005 | 2477 | 0.010 |
Why?
|
Punctures | 1 | 2000 | 366 | 0.010 |
Why?
|
Vitamin B 12 | 1 | 1981 | 524 | 0.010 |
Why?
|
Survivors | 1 | 2009 | 2371 | 0.010 |
Why?
|
Patient Admission | 1 | 2004 | 1367 | 0.010 |
Why?
|
Demography | 1 | 2002 | 1648 | 0.010 |
Why?
|
Evidence-Based Medicine | 1 | 2009 | 3688 | 0.010 |
Why?
|
Factor XII Deficiency | 1 | 1996 | 3 | 0.010 |
Why?
|
Motor Neurons | 1 | 1981 | 870 | 0.010 |
Why?
|
Antibodies, Antiphospholipid | 1 | 1996 | 71 | 0.010 |
Why?
|
Syndrome | 1 | 2002 | 3267 | 0.010 |
Why?
|
Mental Health | 2 | 2000 | 3250 | 0.010 |
Why?
|
Radiographic Image Enhancement | 1 | 1999 | 876 | 0.010 |
Why?
|
Emergencies | 1 | 2001 | 1217 | 0.010 |
Why?
|
Educational Status | 1 | 2000 | 2522 | 0.010 |
Why?
|
Tomography, X-Ray Computed | 1 | 2015 | 20568 | 0.010 |
Why?
|
Data Interpretation, Statistical | 1 | 2000 | 2691 | 0.010 |
Why?
|
Chronic Disease | 1 | 2004 | 9319 | 0.010 |
Why?
|
Forecasting | 1 | 1998 | 2928 | 0.000 |
Why?
|
Neoplasms | 1 | 2015 | 22173 | 0.000 |
Why?
|
Adolescent | 1 | 2011 | 88326 | 0.000 |
Why?
|
Animals | 1 | 2011 | 168475 | 0.000 |
Why?
|